Cargando…

Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy

Neutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiahui, Ji, Cheng, Zhang, Hongbo, Shi, Hui, Mao, Fei, Qian, Hui, Xu, Wenrong, Wang, Dongqing, Pan, Jianming, Fang, Xinjian, Santos, Hélder A., Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754405/
https://www.ncbi.nlm.nih.gov/pubmed/35020437
http://dx.doi.org/10.1126/sciadv.abj8207
_version_ 1784632266526294016
author Zhang, Jiahui
Ji, Cheng
Zhang, Hongbo
Shi, Hui
Mao, Fei
Qian, Hui
Xu, Wenrong
Wang, Dongqing
Pan, Jianming
Fang, Xinjian
Santos, Hélder A.
Zhang, Xu
author_facet Zhang, Jiahui
Ji, Cheng
Zhang, Hongbo
Shi, Hui
Mao, Fei
Qian, Hui
Xu, Wenrong
Wang, Dongqing
Pan, Jianming
Fang, Xinjian
Santos, Hélder A.
Zhang, Xu
author_sort Zhang, Jiahui
collection PubMed
description Neutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. In addition, we decorated N-Ex with superparamagnetic iron oxide nanoparticles (SPIONs) to achieve higher tumor-targeting therapeutic effect. We further fabricated exosome-like nanovesicles from neutrophils (NNVs) at high yield. Compared with liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs show an improved inhibition of tumor cell proliferation. Moreover, DOX-loaded, SPION-decorated NNVs selectively accumulate at the tumor sites under an external magnetic field, effectively restraining tumor growth and extensively prolonging the survival rate in mice. Overall, a simple and effective method to engineer N-Ex and NNVs at clinical applicable scale was developed, which enables the efficient and safe drug delivery for targeted and combined tumor therapy.
format Online
Article
Text
id pubmed-8754405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-87544052022-01-27 Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy Zhang, Jiahui Ji, Cheng Zhang, Hongbo Shi, Hui Mao, Fei Qian, Hui Xu, Wenrong Wang, Dongqing Pan, Jianming Fang, Xinjian Santos, Hélder A. Zhang, Xu Sci Adv Biomedicine and Life Sciences Neutrophils are the most abundant innate immune cells in human circulation; however, their derived exosomes have been rarely studied for tumor treatment. Here, we reported that exosomes from neutrophils (N-Ex) induce tumor cell apoptosis by delivering cytotoxic proteins and activating caspase signaling pathway. In addition, we decorated N-Ex with superparamagnetic iron oxide nanoparticles (SPIONs) to achieve higher tumor-targeting therapeutic effect. We further fabricated exosome-like nanovesicles from neutrophils (NNVs) at high yield. Compared with liposome-loaded doxorubicin (DOX) and natural NNVs, DOX-loaded NNVs show an improved inhibition of tumor cell proliferation. Moreover, DOX-loaded, SPION-decorated NNVs selectively accumulate at the tumor sites under an external magnetic field, effectively restraining tumor growth and extensively prolonging the survival rate in mice. Overall, a simple and effective method to engineer N-Ex and NNVs at clinical applicable scale was developed, which enables the efficient and safe drug delivery for targeted and combined tumor therapy. American Association for the Advancement of Science 2022-01-12 /pmc/articles/PMC8754405/ /pubmed/35020437 http://dx.doi.org/10.1126/sciadv.abj8207 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Zhang, Jiahui
Ji, Cheng
Zhang, Hongbo
Shi, Hui
Mao, Fei
Qian, Hui
Xu, Wenrong
Wang, Dongqing
Pan, Jianming
Fang, Xinjian
Santos, Hélder A.
Zhang, Xu
Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title_full Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title_fullStr Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title_full_unstemmed Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title_short Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
title_sort engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754405/
https://www.ncbi.nlm.nih.gov/pubmed/35020437
http://dx.doi.org/10.1126/sciadv.abj8207
work_keys_str_mv AT zhangjiahui engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT jicheng engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT zhanghongbo engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT shihui engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT maofei engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT qianhui engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT xuwenrong engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT wangdongqing engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT panjianming engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT fangxinjian engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT santosheldera engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy
AT zhangxu engineeredneutrophilderivedexosomelikevesiclesfortargetedcancertherapy